Seattle Genetic has grown from a small therapeutics company to the current highly equipped research and development firm that is offering solutions for the treatment of cancer and other ailments. One of the co-founders of the company, Clay Siegall, has showed a lot of passion for the industry and this has earned him a name as far as research and management is concerned.
His prowess in clinical research and drug manufacturing and managerial skills saw Siegall get an appointment to work as a member of Mirma Therapeutics’s Board of Directors. Mirna Therapeutics is a Texas-based therapeutics company that was established in 2007 that deals with microRNA therapeutics and its focus of late has been directed at cancer research, something Dr. Clay B. Siegall is well equipped in.
Founded in 1998, Seattle Genetics has grown and achieved a lot in the domain of cancer research. They have been making clinical and preclinical products over the years and have teamed up with leading companies like GlaxoSmithKline to offer products that are focused on treating specific diseases.
One of the most successful products that comes from Seattle Genetics is the antibody-drug conjugate (ADC) meant for treating cancer. The product is based on rigorous research and scientific innovation as well as development.
The ADC technology used in the manufacture of the product ensures the toxic effects of chemotherapy are reduced while at the same time boosting antitumor activity. Seattle Genetics offers these products in different variations like SGN-CD33A applied in treating acute myeloid leukemia and SGN-CD19A applied in non-Hodgkin lymphoma.
About Clay B. Siegall, CEO, Seattle Genetics
Clay B. Siegall is the current Chief Executive Officer at Seattle Genetics. He is responsible for the establishment of Seattle Genetics in 1998 together with other founding members and since then he has held the Chairmanship of the Board. Siegall is trained as a clinical scientist and this explains the reason he runs the company on a foundation of research and innovation that leads to useful drug development.
Before founding Seattle Genetics, Clay Siegall worked with Bristol-Meyers Research Institute between 1991 and 1997. He has also received several awards including the one issued in 2013 by the University of Maryland for the Alumnus of the Year in Math, Computer and Natural Sciences.